ArticleFrontiers in microbiology2025
Effect of encapsulation technology and
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microencapsulation ofFrontiers in microbiology · 2026Article
- Supplementation with abioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Members of the Lactobacillaceae family have been extensively investigated for their health-promoting properties, including the restoration of cellular functions, inhibition of pathogen colonization, and cholesterol-lowering effects. Methodology: This study evaluated the hypocholesterolemic activity of Results: The strain demonstrated a pronounced ability to deconjugate taurine-conjugated bile salts, particularly taurocholic acid sodium (TCA) and sodium taurodeoxycholate acid (TDCA), as evidenced by viable cell counts. In bioreactor samples, counts reached 8.31 and 7.82 log CFU/mL for TCA and TDCA, respectively. After capsule dissolution, viability decreased across all formulations: C1 showed 6.90 and 5.04, C2 reached 4.99 and 4.68, and C3 recorded 6.10 and 4.12 log CFU/mL. Following Discussion: These findings demonstrate that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.